INTRODUCTION
============

The *N-ras* oncogene is a member of a family of membrane-associated proteins that instigate signal transduction upon ligand binding to a variety of membrane receptors. N-ras proteins regulate cell proliferation, differentiation, and apoptosis by cycling between active GTP-bound and inactive GDP-bound conformations \[[@B1], [@B2]\]. The most common mutations involve a single base substitution in codon 12, 13, or 61 and lead to constitutively active Ras. In its constitutively active, GTP-bound state, Ras induces uncontrolled cell proliferation and inhibits apoptosis \[[@B1], [@B2]\]. *N-ras* mutations have been identified in various solid tumors as well as hematologic malignancies \[[@B2]\]. The prognostic significance of *N-ras* mutations is still unclear. Some groups have proposed that *Ras* mutations are related to a better prognosis \[[@B3]\], whereas others have proposed that mutated *Ras* genes are associated with short survival \[[@B4]\], and many others have been unable to verify the clinical significance of *Ras* mutations \[[@B5]-[@B13]\].

Most recent studies examining the presence of *Ras* mutations in cancer cells have been performed using PCR followed by dideoxy DNA sequencing or conformation-based separation such as single strand conformation polymorphism (SSCP), denaturing gradient gel electrophoresis, restriction fragment length polymorphism (RFLP), or HPLC \[[@B6], [@B8]-[@B11]\]. However, these techniques are labor intensive and time consuming and are therefore not suitable for routine clinical practice. Furthermore, it has been reported that SSCP analysis gives false-negative results in approximately 33% of cases identified as positive \[[@B14]\]. Sanger sequencing is the most commonly used sequencing method; however, it does not detect some mutant sequences that are present in the background of abundant wild-type DNA sequences. Compared with dideoxy sequencing, pyrosequencing has greater analytical sensitivity for the detection of mutant DNA mixed with wild-type DNA. Pyrosequencing is a simple, real-time, non-electrophoretic, high-throughput mutation detection assay that can be applied to large clinical studies \[[@B15]-[@B17]\]. However, the practical aspects and efficiency of pyrosequencing for the analysis of *N-ras* mutations have not been evaluated in clinical settings.

The purpose of this study was to detect *N-ras* mutations in 83 Korean adult patients with AML and to compare the performance of a pyrosequencing kit to a direct sequencing method for the detection of *N-ras* mutations.

METHODS
=======

1. Patients
-----------

Eighty-three adult patients that attended the Hematology and Oncology Department, Gachon University Gil Medical Center, Incheon, Korea from May 2004 to February 2011 were enrolled to analyze the biological and prognostic impact of *N-ras* mutations. The median age of the study population was 55.0 yr (range: 20.0-88.0 yr). A large proportion (43.4%; 36 patients) of patients were older than 65 yr. The male-to-female ratio was 1.3:1 (47 men: 36 women). All patients were newly diagnosed with AML, except some patient with t(15;17) who were diagnosed with acute promyelocytic leukemia (APL). Informed consent for tissue collection and the research studies was approved by the Institutional Review Board of Gachon University Gil Medical Center. The patients were observed from May 2004 to January 2012. Bone marrow (BM) aspirates and biopsy specimen slides were classified into AML subtypes according to the WHO (2008) classifications \[[@B18]\]. The following clinical characteristics were analyzed at diagnosis: age, sex, hemoglobin, peripheral white blood cell (WBC) count, platelet count, serum lactate dehydrogenase (LDH) concentration, cytogenetic findings, and percentage of blasts in BM aspirates. After the induction and consolidation of chemotherapy, the patients were reevaluated for clinical and cytological findings of leukemia or treatment response. Complete remission (CR) was defined as a normocellular BM containing fewer than 5% blasts.

Of the 83 patients, 58 were treated with a standard protocol, 45 patients received only standard chemotherapy, and 13 patients were treated with standard chemotherapy as well as BM transplantation (BMT). Due to the physical condition of the older patients, 10 patients were given palliative low-dose 1-β-D-arabinofuranosylcytosine (Ara-C) treatment only. During the course of this study, 7 patients were transferred to other hospitals or were lost to follow-up therapies. Another 8 patients were denied therapy.

2. Cytogenetic studies
----------------------

Chromosomal analysis was performed on the BM aspirates by G-banding. Karyotypes were designated according to the International System for Human Cytogenetic Nomenclature (2009) \[[@B19]\].

3. Detection of somatic mutations by PCR
----------------------------------------

RNA from the BM aspirates was extracted using the Qiagen RNeasy Mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer\'s instructions. After reverse transcription PCR using the Pure Extreme kit (MBI Fermentas, St Leon-Rot, Germany), gene rearrangements were analyzed using Seeplex Leukemia PML/RARa, AML/ETO and BCR/ABL kits (Seegene, Seoul, Korea). DNA from the BM aspirates was isolated using the QIAamp DNA blood mini kit (Qiagen). *FLT3* mutations were confirmed using a Seeplex *FLT3* Genotyping kit (Seegene). These *FLT3* mutations were classified as internal tandem duplication (ITD) mutations or mutation in the tyrosine kinase domain (TKD).

4. Detection of *N-ras* mutations by pyrosequencing and direct sequencing
-------------------------------------------------------------------------

The sample was collected from each patient at diagnosis, and follow-up samples were collected in 6 patients with mutations. We analyzed 90 BM samples from 83 AML patients to detect *N-ras* mutations in codons 12, 13, and 61 using the pyrosequencing; all data were subsequently confirmed by direct sequencing. DNA from the BM aspirates was prepared using the QIAamp DNA blood mini kit (Qiagen). Mutations in the *N-ras* were detected by pyrosequencing using a TheraScreen NRAS Pyro kit (Qiagen). PCR templates for pyrosequencing were amplified from genomic DNA (10 ng) using the Pyro Mark PCR Master mix (Qiagen) and 5 pmol of each primer in a total reaction volume of 25 µL. Following PCR amplification, the biotinylated PCR products were placed in 24-well plates and bound to streptavidin-coated sepharose beads (GE Healthcare, Piscataway, NJ, USA). The PCR products were denatured, and the non-biotinylated fragments were washed from the beads using the Pyromark Q24 Vacuum Workstation (Qiagen). The beads were then resuspended in annealing buffer (24.2 µL) containing 0.4 pmol of the sequencing primer. Pyrosequencing was performed using the Pyro Gold Q24 reagents (Qiagen), using dispensations based on the target sequence with the Pyromark Q24 system. Raw data files were imported into Pyromark Q24 software (version 2.0; Qiagen) for further analysis following pyrosequencing.

The pyrosequencing data were confirmed by direct sequencing (Macrogen, Seoul, Korea). For the direct sequencing, 100 ng of genomic DNA from the patients was used for PCR with AccuPower PCR PreMix (Bioneer, Seoul, Korea). An initial preheating at 94℃ for 10 min was followed by denaturation at 94℃ for 40 sec, 58℃ for 40 sec, and 72℃ for 40 sec for 35 cycles and a final extension at 72℃ for 7 min. The primer sets used were forward primer 5\'-GTGAGGCCGATATTAATCCG-3\' and reverse primer 5\'-ACAGTCACGCTACTATGGCC-3\' for exon 1 to amplify codons 12 and 13 and forward primer 5\'-GTTATAGATGGTGAAACCTG-3\' and reverse primer 5\'-GCTCTATCTTCCCTAGTGTG-3\' for exon 2 to amplify codon 61. The PCR products were analyzed by direct sequencing using the exon 1 forward primer and the exon 2 reverse primer ([Fig. 1](#F1){ref-type="fig"}).

5. Statistical analysis
-----------------------

The frequency of clinical characteristics was analyzed by Pearson\'s χ^2^ test. Differences in mean variables were analyzed by Mann-Whitney statistics. Cross tabulation was used in comparison between direct sequencing and pyrosequencing. All statistical analyses were performed using the SPSS software package version 17.0 (SPSS Inc., Chicago, IL, USA). For all the analyses, *P* values \<0.05 were considered statistically significant.

RESULTS
=======

The incidence of mutation in the *N-ras* gene was 7.2% in the AML patients. Mann-Whitney statistics revealed that the group of patients with *N-ras* mutations (6 patients) showed higher hemoglobin levels (*P*=0.022), and a higher prevalence rate of *FLT3* mutations in patients with *N-ras* mutations was demonstrated by the Pearson\'s χ^2^ test (*P*=0.003). Among the 83 patients, 15 patients had *FLT3* mutations (18.1%) and 13 of them showed ITD mutations. Two patients had TKD mutations. The incidence of *FLT3* mutations in patients with wild-type *N-ras* was 16.9% (13 of 77 patients) and 33.3% (2 of 6 patients) in patients with the *N-ras* mutation ([Table 1](#T1){ref-type="table"}). Other factors were not statistically correlated with the presence of *N-ras* mutations ([Table 1](#T1){ref-type="table"}). All patients with mutations were diagnosed with *de novo* AML. Five of 6 patients were diagnosed with AML, not otherwise specified (AML, NOS) and 4 of these 6 patients had normal karyotypes ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}).

We observed 3 cases with mutated *N-ras* codon 12 (3.6%), 2 cases with mutated codon 13 (2.4%), and 1 case with mutated codon 61 (1.2%). None of the patients with mutations showed homozygous mutations. The base substitution in codon 12 subsequently led to an amino acid change from wild-type glycine to serine, cysteine, or aspartic acid (G12S, G12C, and G12D). Mutations at codon 13 also induced an amino acid substitution of wild-type glycine to aspartic acid or arginine (G13D and G13R). The mutation in codon 61 caused the glutamine to arginine substitution (Q61R).

We performed pyrosequencing and direct sequencing for all 83 patients. The BM study was performed at initial diagnosis, and the patients who received chemotherapy were re-evaluated for evidence of leukemia or CR after chemotherapy. Seven *N-ras* mutations were detected in 6 cases (7.2%) by both sequencing methods, and there was no difference in the detection rate ([Fig. 2](#F2){ref-type="fig"}). The percentage of *N-ras* mutant DNA assayed for codon 12, 13, and 61 mutations by pyrosequencing was 23%-49% ([Table 3](#T3){ref-type="table"}). In 5 patients, the *N-ras* mutation disappeared from the BM after the induction chemotherapy, and morphological remission in the BM was also evident. Although there was no evidence of leukemic blasts in the BM, the *N-ras* mutation in codon 13 persisted after the induction therapy in 1 patient (sample no. 46). In this patient, the mutated allele burden was similar to that at initial diagnosis (initial, 39%; after induction chemotherapy, 33%) ([Table 3](#T3){ref-type="table"}), and the mutation disappeared after the first consolidation therapy. Of these 6 patients, 4 died, 1 was associated with treatment failure, and only 1 patient reached CR after BMT ([Table 3](#T3){ref-type="table"}).

DISCUSSION
==========

Here, we studied the incidence of *N-ras* mutations in adult patients with AML. The incidence of *N-ras* mutation was 7.2% in the adult patients with AML examined at a single Korean institution. Recent studies have shown that *N-ras* mutation is present in AML patients in the range of 7.03-20.26%, and this value is reduced in Asian countries \[[@B6]-[@B13]\] ([Table 4](#T4){ref-type="table"}).

Compared to the total patient pool in this study, the patients with *N-ras* mutations (6 patients) showed higher hemoglobin levels (*P*=0.022) and a higher prevalence of *FLT3* mutations (*P*=0.003). Other factors did not correlate with the presence of *N-ras* mutations.

We identified both *N-ras* mutation and *FLT3*-TKD mutation in 2 patients that presented with normal karyotypes. Whitman et al. \[[@B20]\] reported that younger adults with *de novo* CN-AML and *FLT3*-TKD mutations in D835/I836 are associated with worse outcome than those without *FLT3*-TKD mutations. A previous report by Illmer et al. \[[@B21]\] stated that AML patients with high Ras activity were highly sensitive to high doses of Ara-C and that Ras activity may overcome the poor prognosis in younger patients even in the presence of *FLT3* mutations. In our study, case 71 had both *N-ras* mutation and *FLT3*-TKD mutation, and she was treated with palliative low doses of Ara-C because of her old age (81 yr old); she passed away 1 month after diagnosis. The other patient with both mutations (sample no. 58) who was younger (47 yr old) showed induction failure and demonstrated CR after a high dose of Ara-C treatment and allogenic BMT. These findings are consistent with the conjecture that aggressive treatments are required for the patients with *N-ras* and *FLT3*-TKD mutations.

In this study, all *N-ras* mutations were observed in *de novo* AML, but 94.0% of the enrolled patients were diagnosed with *de novo* AML. Therefore, the result could not reflect a relationship between the subtype of AML and the incidence of *N-ras* mutation. Two of the 6 patients were diagnosed with acute myelomonocytic/monocytic leukemia. Several studies have reported that *N-ras* mutations promote myeloid maturation defects with relative sparing of the monocyte lineage. In addition, *Ras* mutations are particularly prevalent in leukemia and preleukemia with monocytic characteristics \[[@B3], [@B5], [@B6], [@B22]\].

All point mutations in *N-ras* induced an amino acid change. In 3 patients, a G→A base substitution in codon 12 and 13 was detected; this is the most commonly reported base substitution in *Ras* mutations in AML \[[@B23], [@B24]\]. The glycine residue located in position 12 (Gly12) lies close to the \"finger loop\" of the GTPase activating proteins (GAP) that complements the active site of Ras. Any mutation at this position results in sterical interference with the geometry of the transition state, in which GTP is hydrolyzed in the presence of GAP fingers \[[@B1]\]. It has been reported that G12D shortens disease latency rather than contributing to tumorigenesis \[[@B25], [@B26]\]. We found that 2 of 3 patients with *N-ras* mutations in codon 12 died within 1 month after diagnosis; one of them had a G12D mutation. The other patient revealed re-induction failure and was lost to follow up ([Table 3](#T3){ref-type="table"}).

All *N-ras* mutations disappeared during chemotherapy, thereby suggesting a relationship between the presence of *N-ras* mutation and disease status. In one patient (case 46), leukemic blasts were not detected in BM, and chromosomal abnormalities present at initial diagnosis (46,XY,del(9)(q21q22)\[[@B25]\]/46,XY\[[@B5]\]) also disappeared after the induction chemotherapy. Nevertheless, the *N-ras* mutation persisted after the induction chemotherapy, and the level of the mutated gene (33%) was similar to the level at initial diagnosis (39%) ([Table 3](#T3){ref-type="table"}). After first consolidation chemotherapy, direct sequencing and pyrosequencing in case 46 did not detect the *N-ras* mutation. In the study by Bacher et al. \[[@B5]\], they concluded that *N-ras* mutations were not a good marker for follow-up control \[[@B5]\]. However, our study shows that monitoring *N-ras* mutations can be a more sensitive indicator of therapeutic response than morphologic or conventional cytogenetic studies.

In this study, pyrosequencing and direct sequencing showed same efficiencies with respect to their ability to detect mutations. During the therapeutic period, the number of leukemic cells decreases, and, in some cases, it is difficult to discriminate these cells from normal early precursor cells. A low limit of detection (LOD) of pyrosequencing is important in cases with rare mutations as well as in follow-up studies for early detection of relapse in patients with AML \[[@B17], [@B27]\]. Athanasios et al. \[[@B16]\] determined that the LOD for Sanger sequencing, pyrosequencing, and melting curve analysis is approximately 15-20%, 5%, and 10% mutant alleles, respectively. Another advantage of pyrosequencing is that it can read a starting sequence from the first nucleotide adjacent to a pyrosequencing primer without a noise signal. In addition, pyrosequencing is a simple, one-step method that is efficient because 24 samples can be analyzed in \<40 min. Pyrosequencing is a simple method compared with Sanger sequencing and does not require a separate purification step or gel electrophoresis after PCR. However, there is a limitation in pyrosequencing kits because only a few positions (≤40-50 nucleotides) can be simultaneously analyzed, and it costs more than other methods (100,000-150,000 KRW/sample) \[[@B17], [@B28], [@B29]\].

In our study, the numbers of patients and *N-ras* mutation cases were too small to make any statistical conclusions. In addition, because the patients received different treatments, it was difficult to compare the outcome and prognostic effect of the *N-ras* mutations. Many factors may contribute to the clinical outcome associated with the presence of *N-ras* mutations, and our analysis investigated only a few of them.

This study is important because there are no recent reports analyzing the presence of *N-ras* mutations in the Korean patients with hematologic malignancies. This study identified the incidence of *N-ras* mutations (7.2%) in patients with AML at a single Korean institution and revealed the relationship between the presence of *N-ras* mutation and the therapeutic response. We also evaluated the pyrosequencing kit for *N-ras* mutation detection as a confirmatory test to identify specific mutations. The same efficiency with respect to the detection of *N-ras* mutations was determined for pyrosequencing and direct sequencing. Because pyrosequencing provides quantitative data and information regarding the mutation type, it is a useful tool for detecting malignant cells and for following patients\' progress. Finally, it may be appropriate for large-scale applications in clinical settings for the analysis of hematologic malignancies.
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![Schematic representation of the location of the direct sequencing primers on the *N-ras* codons 12, 13, and 61. Codons 12 and 13 are located in exon 1, and codon 61 is in exon 2. For the detection of mutations in codon 12 and 13, PCR products of 607 nucleotides were analyzed. Mutations in codon 61 were detected by sequencing the PCR product of exon 2 (248 nucleotides).](alm-33-159-g001){#F1}

![*N-ras* mutations established by pyrosequencing and confirmed by direct sequencing. (A) Pyrogram showing the presence of mutation and quantitative data of mutated clones. The horizontal axis refers to the base, and the vertical axis represents the intensity of the fluorescent signal. The shaded regions represent the analyzed codon. The first box shows the analytic results of substitutions in the first base of the *N-ras* codons 12 and 13. The second box presents mutations in the second base of the *N-ras* codons 12 and 13. The third box shows a positive result for a mutation in the second base of codon 61. (B) All patient samples were confirmed by direct sequencing, and the plots showed the same results as pyrosequencing.](alm-33-159-g002){#F2}

###### 

Characteristics of AML patients with or without *N-ras* mutations
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Abbreviations: WBC, white blood cell; PLT, platelet; BM, bone marrow; LDH, lactose dehydrogenase; *FLT3*, FMS-like tyrosine kinase 3.
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History of AML and cytogenetics
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Abbreviations: s-AML, secondary AML; t-AML, therapy related AML; AML with MRC, AML with myelodysplasia-related changes; AML, NOS, AML, not otherwise specified.
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Characteristics of AML patients with *N-ras* mutation and sequencing results
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^\*^After induction chemotherapy, the *N-ras* mutation in codon 13 persisted and the mutated allele burden was similar to that at initial diagnosis.

AML, NOS, AML, not otherwise specified.

Abbreviations: CTx, chemotherapy; BMT, bone marrow transplantation; AML with MRC, AML with myelodysplasia-related changes; D835Y, *FLT3* kinase domain point mutation.
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Recent *N-ras* mutation studies in AML patients
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Abbreviations: PNA, peptide nucleic acid; DHPLC, denaturing high performance liquid chromatography; RFLP, restriction fragment length polymorphism; SSCP, single-strand conformation polymorphism analysis; MALDI-TOF MS, matrix-assisted laser desorption/ionisation-time of flight mass spectrometry.
